Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
OMGA Omega Therapeutics
7.050
+0.050+0.71%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
595K 476K 268K 144K
Operating revenue
-- 595K -- 476K -- 268K -- 144K
Cost of revenue
Gross profit
Operating expense
54.35% 26.58M 73.17% 26.33M 56.29% 20.23M 131.02% 66.18M
Selling and administrative expenses
16.57% 5.2M 70.53% 6.2M 96.94% 5.41M 166.24% 16.6M
-General and administrative expense
16.57% 5.2M 70.53% 6.2M 96.94% 5.41M 166.24% 16.6M
Research and development costs
68.20% 20.67M 73.35% 19.39M 45.58% 14.19M 127.25% 47.87M
Other operating expenses
50.53% 712K 92.97% 741K 40.31% 630K 26.89% 1.71M
Operating profit
-50.89% -25.99M -70.04% -25.85M -54.22% -19.96M -130.52% -66.03M
Net non-operating interest income expense
154.28% 184K 71.05% -55K 26.89% -155K -17.12% -910K
Non-operating interest expense
-- -- -71.05% 55K -26.89% 155K 17.12% 910K
Total other finance cost
-- -184K -- -- -- -- -- --
Other net income (expense)
100.21% 2K 80.00% -3K 85.03% -50K -5,252.00% -1.34M
Gain on sale of security
-- -- -- -- -- -- -- -1.31M
Other non- operating income (expenses)
0.00% 2K 25.00% -3K -1,150.00% -50K -12.00% -28K
Income before tax
-39.24% -25.8M -68.15% -25.91M -49.50% -20.16M -131.87% -68.28M
Income tax
Net income
-39.24% -25.8M -68.15% -25.91M -49.50% -20.16M -131.87% -68.28M
Net income continuous Operations
-39.24% -25.8M -68.15% -25.91M -49.50% -20.16M -131.87% -68.28M
Minority interest income
Net income attributable to the parent company
-39.24% -25.8M -68.15% -25.91M -49.50% -20.16M -131.87% -68.28M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-39.24% -25.8M -68.15% -25.91M -49.50% -20.16M -131.87% -68.28M
Basic earnings per share
5.26% -0.54 -63.74% -0.54 2.33% -0.42 -167.54% -3.05
Diluted earnings per share
5.26% -0.54 -63.74% -0.54 2.33% -0.42 -167.54% -3.05
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.
CEO: Mr. Mahesh Karande
Market: NASDAQ
Listing Date: 07/30/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist